Director Sharon Barbari not standing for re-election at Sonoma Pharma annual meeting

Sonoma Pharmaceuticals, Inc.

Director Sharon Barbari notified company on July 27, 2021 she will not stand for re-election at Sep 15, 2021 annual meeting due to personal reasons.
No disagreements between Barbari and the company; board thanked her for over seven years of service.
Company is currently searching for a new board member to replace Barbari.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Sharon Barbari

Director

SNOA · Sonoma Pharmaceuticals, Inc.

Effective: 2021-09-15
Filed: August 2, 2021, 7:59 PM ET

On July 27, 2021, Sharon Barbari, our director, chair of the audit committee and member of the compensation and nominating and corporate governance committee notified us that she does not intend to stand for re-election at out upcoming annual meeting of stockholders on September 15, 2021 due to personal reasons.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sharon Barbari departed as Director at Sonoma Pharmaceuticals, Inc..

Action: notified that she does not intend to stand for re-election
Role: Director

Exact text from the filing

On July 27, 2021, Sharon Barbari, our director, chair of the audit committee and member of the compensation and nominating and corporate governance committee notified us that she does not intend to stand for re-election at out upcoming annual meeting of stockholders on September 15, 2021 due to personal reasons.

View on SEC.gov

Sonoma Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-21-003217

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.